Compare Elder Pharma with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs NEULAND LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA NEULAND LABS ELDER PHARMA/
NEULAND LABS
 
P/E (TTM) x -0.2 49.5 - View Chart
P/BV x 0.1 3.7 2.7% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ELDER PHARMA   NEULAND LABS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
NEULAND LABS
Mar-20
ELDER PHARMA/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs380754 50.4%   
Low Rs188247 76.0%   
Sales per share (Unadj.) Rs491.2594.5 82.6%  
Earnings per share (Unadj.) Rs-3.212.6 -25.2%  
Cash flow per share (Unadj.) Rs14.437.0 38.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs376.5553.4 68.0%  
Shares outstanding (eoy) m20.5412.83 160.1%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.60.8 68.7%   
Avg P/E ratio x-89.339.6 -225.3%  
P/CF ratio (eoy) x19.713.5 145.8%  
Price / Book Value ratio x0.80.9 83.4%  
Dividend payout %015.8 0.0%   
Avg Mkt Cap Rs m5,8336,421 90.9%   
No. of employees `000NA1.3 0.0%   
Total wages/salary Rs m2,1791,236 176.4%   
Avg. sales/employee Rs ThNM5,949.4-  
Avg. wages/employee Rs ThNM963.8-  
Avg. net profit/employee Rs ThNM126.4-  
INCOME DATA
Net Sales Rs m10,0897,627 132.3%  
Other income Rs m25739 660.5%   
Total revenues Rs m10,3467,666 135.0%   
Gross profit Rs m-7921,019 -77.7%  
Depreciation Rs m361313 115.5%   
Interest Rs m2,756216 1,277.7%   
Profit before tax Rs m-3,653529 -690.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125367 34.1%   
Profit after tax Rs m-65162 -40.3%  
Gross profit margin %-7.813.4 -58.8%  
Effective tax rate %-3.469.4 -4.9%   
Net profit margin %-0.62.1 -30.5%  
BALANCE SHEET DATA
Current assets Rs m9,2405,152 179.4%   
Current liabilities Rs m9,9983,576 279.6%   
Net working cap to sales %-7.520.7 -36.4%  
Current ratio x0.91.4 64.2%  
Inventory Days Days46105 44.1%  
Debtors Days Days6091 66.0%  
Net fixed assets Rs m10,1243,969 255.1%   
Share capital Rs m206129 159.5%   
"Free" reserves Rs m5,5826,971 80.1%   
Net worth Rs m7,7347,100 108.9%   
Long term debt Rs m4,889774 631.9%   
Total assets Rs m22,88212,310 185.9%  
Interest coverage x-0.33.5 -9.4%   
Debt to equity ratio x0.60.1 580.1%  
Sales to assets ratio x0.40.6 71.2%   
Return on assets %11.83.1 383.2%  
Return on equity %-0.82.3 -37.0%  
Return on capital %22.39.5 235.8%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3075,187 5.9%   
Fx outflow Rs m1251,593 7.9%   
Net fx Rs m1813,594 5.0%   
CASH FLOW
From Operations Rs m11,754573 2,049.9%  
From Investments Rs m-561-487 115.1%  
From Financial Activity Rs m-6,762-55 12,339.1%  
Net Cashflow Rs m4,43233 13,594.2%  

Share Holding

Indian Promoters % 39.6 36.3 109.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 63.7 11.8%  
FIIs % 16.8 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 63.7 56.6%  
Shareholders   16,479 12,705 129.7%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   STRIDES PHARMA SCIENCE  CADILA HEALTHCARE  SUVEN LIFE SCIENCES  ALEMBIC PHARMA  WOCKHARDT  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS